Literature DB >> 19294502

The distribution over time of costs and social net benefits for pertussis immunization programs.

Dorota Zdanowska Girard1.   

Abstract

The cost of a six-dose pertussis immunization programs for children and adolescents is investigated in relation to estimators of the price of acellular vaccine, the value of a child's life, levels of vaccination rate and discount rates. We compare the cost of the program maintained over time at 90% with three alternative strategies, each involving a decrease in vaccination coverage. Data from England and Wales, 1966-2005, is used to formalize a delay in occurrence of pertussis cases as a result of a fall in coverage. We first apply the criterion of minimization of the total social cost of pertussis to identify the best cost saving immunization strategy. The results are also discussed in form of the discounted present value of the total social net benefits. We find that the discounted present value of the total social net benefit is maximized when a stable vaccination program at 90% is compared to a gradual decrease in vaccination coverage leading to the lowest vaccination rate. The benefits to society of providing sustained immunization strategy, vaccinating the highest proportion of children and adolescents, are systematically proved on the basis of the second optimisation criterion, independently of the level of estimators applied during economic evaluation for the cost variables.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19294502     DOI: 10.1007/s10754-009-9058-2

Source DB:  PubMed          Journal:  Int J Health Care Finance Econ        ISSN: 1389-6563


  36 in total

1.  Intervention times series analysis of pertussis vaccination in England and Wales.

Authors:  D Z Girard
Journal:  Health Policy       Date:  2000-11-01       Impact factor: 2.980

2.  QALYs versus WTP.

Authors:  James K Hammit
Journal:  Risk Anal       Date:  2002-10       Impact factor: 4.000

3.  Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents.

Authors:  N N Tran Minh; Q He; A Ramalho; A Kaufhold; M K Viljanen; H Arvilommi; J Mertsola
Journal:  Pediatrics       Date:  1999-12       Impact factor: 7.124

4.  Comparison of 13 acellular pertussis vaccines: adverse reactions.

Authors:  M D Decker; K M Edwards; M C Steinhoff; M B Rennels; M E Pichichero; J A Englund; E L Anderson; M A Deloria; G F Reed
Journal:  Pediatrics       Date:  1995-09       Impact factor: 7.124

5.  Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costs.

Authors:  A R Hinman; J P Koplan
Journal:  JAMA       Date:  1984-06-15       Impact factor: 56.272

6.  Parents' preferences for outcomes associated with childhood vaccinations.

Authors:  M Kuppermann; R F Nease; L M Ackerson; S B Black; H R Shinefield; T A Lieu
Journal:  Pediatr Infect Dis J       Date:  2000-02       Impact factor: 2.129

Review 7.  Epidemiology of pertussis.

Authors:  Tina Tan; Evelinda Trindade; Danuta Skowronski
Journal:  Pediatr Infect Dis J       Date:  2005-05       Impact factor: 2.129

8.  Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study.

Authors:  J A Englund; M D Decker; K M Edwards; M E Pichichero; M C Steinhoff; E L Anderson
Journal:  Pediatrics       Date:  1994-01       Impact factor: 7.124

9.  Pertussis--United States, January 1992-June 1995.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1995-07-21       Impact factor: 17.586

10.  Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine. A population-based case-control study.

Authors:  J L Gale; P B Thapa; S G Wassilak; J K Bobo; P M Mendelman; H M Foy
Journal:  JAMA       Date:  1994-01-05       Impact factor: 56.272

View more
  1 in total

Review 1.  Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.